Greg Yap
Overview
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Genomics.
Portfolio Companies
Reach Greg Yap directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Greg Yap
What sectors does Greg Yap invest in?
Greg Yap invests in BioTech, Health & Hospital Services, Health IT, Medical Devices, Consumer and Cybersecurity, and is based in Palo Alto, California. Greg Yap is listed as a investor in the ConnectSafely investor database.
What stage does Greg Yap invest at?
Greg Yap backs companies at Seed, Series A and Series B, writing cheques of $100K - $500K.
Which regions does Greg Yap invest in?
Greg Yap invests across US/Canada.
What companies has Greg Yap invested in?
Greg Yap's portfolio includes Benchling.
How do I contact Greg Yap?
Greg Yap's contact details — including work email and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database